Literature DB >> 6419316

Pathogenesis of Pseudomonas aeruginosa ocular diseases.

A S Kreger.   

Abstract

The gram-negative opportunistic bacterial pathogen, Pseudomonas aeruginosa, is an important etiologic agent of a variety of infectious diseases affecting the eye and surrounding tissues. The number of clinical studies and studies with mouse, guinea pig, and rabbit models of Pseudomonas-induced ocular disease has increased markedly in recent years, and this research has led to our improved understanding of factors relating to the pathogenesis and management of the diseases. Factors that predispose to ocular infections with P. aeruginosa include (1) trauma to the cornea with, or implantation of, foreign bodies or substances contaminated with the bacteria; (2) the presence of preexisting ocular disease; (3) immunosuppressive chemotherapy; and (4) presumed immunoincompetency in premature infants. The results of studies with animal models support the idea that the severe corneal damage that occurs during pseudomonas keratitis is caused by the production of bacterial enzymes and toxins that injure or kill the cellular components and/or degrade the extracellular matrix of the cornea and by bacterial product-mediated release or activation of cornea-degrading enzymes from corneal cells and/or from polymorphonuclear leukocytes infiltrating the infected cornea.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6419316     DOI: 10.1093/clinids/5.supplement_5.s931

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  9 in total

1.  A Mouse Model for Ocular Surface Staphylococcus aureus Infection.

Authors:  Zhiyong Zhang; Osama Abdel-Razek; Guirong Wang
Journal:  Curr Protoc Mouse Biol       Date:  2017-03-02

2.  A Novel, Broad-Spectrum Antimicrobial Combination for the Treatment of Pseudomonas aeruginosa Corneal Infections.

Authors:  Michaelle Chojnacki; Alesa Philbrick; Tyler Scherzi; Nicole Pecora; Paul M Dunman; Rachel A F Wozniak
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

3.  Kinetics of serum, tear, and corneal antibody responses in resistant and susceptible mice intracorneally infected with Pseudomonas aeruginosa.

Authors:  M J Preston; K A Kernacki; J M Berk; L D Hazlett; R S Berk
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

4.  Pseudomonas and neutrophil products modify transferrin and lactoferrin to create conditions that favor hydroxyl radical formation.

Authors:  B E Britigan; B L Edeker
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

5.  Protease-cleaved iron-transferrin augments oxidant-mediated endothelial cell injury via hydroxyl radical formation.

Authors:  R A Miller; B E Britigan
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

6.  Protease cleavage of iron-transferrin augments pyocyanin-mediated endothelial cell injury via promotion of hydroxyl radical formation.

Authors:  R A Miller; G T Rasmussen; C D Cox; B E Britigan
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

7.  Serum antibody response to Pseudomonas aeruginosa antigens during corneal infection.

Authors:  M J Preston; J M Berk; L D Hazlett; R S Berk
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

8.  Permeability factor, cytotoxicity and serotyping of Pseudomonas aeruginosa strains.

Authors:  A Hostacká; V Majtán
Journal:  Folia Microbiol (Praha)       Date:  1992       Impact factor: 2.099

9.  Elevated c-di-GMP Levels and Expression of the Type III Secretion System Promote Corneal Infection by Pseudomonas aeruginosa.

Authors:  Joey Kuok Hoong Yam; Thet Tun Aung; Song Lin Chua; Yingying Cheng; Gurjeet Singh Kohli; Jianuan Zhou; Florentin Constancias; Yang Liu; Zhao Cai; May Margarette Santillan Salido; Daniela I Drautz-Moses; Scott A Rice; Stephan Christoph Schuster; Zhao Zhi Boo; Bin Wu; Staffan Kjelleberg; Tim Tolker-Nielsen; Rajamani Lakshminarayanan; Roger W Beuerman; Liang Yang; Michael Givskov
Journal:  Infect Immun       Date:  2022-08-01       Impact factor: 3.609

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.